English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 24 March 2021, 05:00 HKT/SGT
Share:
    

Source: TrialWire
TrialWire launches StudyBoost, the Clinical Trial Insurance Plan
A monthly insurance plan that provides an instant patient recruitment boost at any time, across one or all sites depending on recruitment needs.

SYDNEY & SAN FRANCISCO, Mar 24, 2021 - (ACN Newswire) - TrialWire(TM), the most secure digital Patient Recruitment Platform, announces the launch of StudyBoost, the monthly insurance plan that provides an instant patient recruitment boost at any time, across one or all sites, depending on recruitment needs.

TrialWire, algorithm powered recruitment platform, launches StudyBoost, a Clinical Trial insurance plan. (3/2021)

With more than 80% of clinical trials failing to recruit patients on time, 30% of research sites not able to meet enrollment goals, and 10% of sites not enrolling any patients, StudyBoost offers peace of mind to Clinical Directors and their CROs.

StudyBoost was designed so that sponsors can avoid trial rescue crisis, saving valuable time and money. If a study needs extra patients, StudyBoost can start delivering instantly and at a significantly reduced cost to normal recruitment. There are no project fees and there is a 50% fee reduction for enrolled patient success.

StudyBoost is ideal for sponsors and CROs wanting to avoid extended recruitment stalls while they find a recruitment firm and process engagement documentation, which can take weeks. StudyBoost means any study has a recruitment booster plan ready to action whenever recruitment slows.

StudyBoost is available via the TrialWire self-serve portal, https://www.trial-wire.com/studyboost/. The package is only available from the start of a study.

About TrialWire(TM) - www.trial-wire.com

The TrialWire(TM) platform is the most secure service, using advanced algorithms to find the right people online that might be suitable for studies listed on the Platform. They are invited to the Platform and taken through the AI-Match screener to determine an exact match to a study-site based or remote/virtual.

No account sign-up is required to find and apply for a study. And unlike all other digital recruitment firms, TrialWire does NOT keep patient details - no databases so no potential privacy breaches. Sponsors are not paying for database building where patients are sent to other studies.

The Platform ingests study data from approved trial registries like ClinicalTrials.gov. It uses advanced algorithms, SEO, search marketing, social media, respected news sites, and wellness blogs and more to find patient/trial matches. The algorithms find people based on detailed demographic and location profiles.

Key to TrialWire success is that it finds motivated people who are online actively trying to find out more about their conditions. These people can be connected to a site in under 2 minutes, and demonstrate the highest retention rates. Learn more about TrialWire at https://www.trial-wire.com.

Contact:
Sydney NSW AUS HQ, +61 2 8218 2145
Singapore APAC HQ, +65 3159 3427
San Francisco USA HQ, +1 415 951 3228
E: team@trial-wire.com, www.trial-wire.com

Topic: Press release summary
Source: TrialWire

Sectors: BioTech, Healthcare & Pharm, MedTech, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

TrialWire Related News
Apr 11, 2023 08:00 HKT/SGT
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%
July 20, 2022 09:00 HKT/SGT
TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally
July 18, 2022 15:00 HKT/SGT
TrialWire(TM) 技術平台宣布基於成功的患者招募計劃
July 18, 2022 15:00 HKT/SGT
TrialWire Technology Platform Announces Success-based Patient Recruitment Plan
July 18, 2022 15:00 HKT/SGT
TrialWire(TM) 技术平台宣布基于成功的患者招募计划
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575